Grünenthal's U.S. subsidiary Averitas Pharma completes recruitment for Phase III clinical trial investigating QUTENZA® for post-surgical neuropathic pain.
Grünenthal's U.S. subsidiary Averitas Pharma completes recruitment for Phase III clinical trial investigating QUTENZA® for post-surgical neuropathic pain.
11/07/24, 1:58 PM
Grünenthal announced the completion of recruitment for the Phase III clinical trial AV001, which evaluates the efficacy, safety, and tolerability of QUTENZA® in treating post-surgical neuropathic pain. The trial aims to provide data that could support a supplemental new drug application to the U.S. FDA in 2026.